Onco Actu du 27 mars 2018

	2. Etiologie
Development of cancer - the luck of the draw? [Institute of Cancer Research] It is difficult to convey the message that the risk of developing cancer is dependent on probabilities. There is a paradox when considering the case of the lifelong heavy smoker who lives into old age without any ill effects, compared to the patient diagnosed with cancer after living a blameless life.
	3.1.1 Prévention - Tabac - e-cigs
Some e-cigarette users may struggle to quit smoking [Reuters] Researchers tested two smoking cessation approaches for 1,357 adult smokers who were hospitalized and expressed a desire to quit. Patients were randomly assigned to receive a free supply of an approved smoking cessation aid or to join a control group that could call a phone hotline for cessation advice.
	3.7 Prévention - Alcool
Lethal labels: Alcohol makers fight to avoid the tobacco taboo [Politico] Booze carries none of the gory images and dire cancer warnings found on cigarette packets.
	4.5 Dép., diag. & prono. - Colorectal
Thousands of bowel cancer patients at risk as hospitals ignore genetic test [The Telegraph] More than eight out of 10 hospitals are ignoring official guidelines by not carrying out screening for Lynch syndrome when patients are diagnosed with the cancer.
	5. Traitements
Women report fewer adverse side-effects from partial or reduced breast radiotherapy, reveals major study [Institute of Cancer Research] The IMPORT LOW trial is the largest randomised trial to study the use of IMRT to deliver partial or low dose breast radiotherapy compared to whole breast radiotherapy, and has provided the largest complete set of patient reported outcome measures data for several points in time over five years.
	5.12.2 Immunothérapies - CAR-T
Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy [Roswell Park] This observation suggests that antibody-based treatment approaches, including survivin CAR T-cell therapy, could be used to target both solid and liquid tumors — a finding that could help broaden the applications for CAR T therapies generally. Current FDA-approved CAR-T therapies are limited to treatments for liquid/hematological cancers.
	5.12.3 Immunothérapies-combinaisons
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week [FiercePharma] Meanwhile, though, plenty of outstanding questions about the data remain—including how much Avastin actually brings to the table.
	5.12.5 Immunothérapies - Pharma
Gilead cancer research director heads to Compugen [FierceBiotech] In Gilead’s latest round of musical chairs, its clinical director of cancer research, Henry Adewoye, M.D., has jumped ship to Compugen, where he will serve as chief medical officer. The move comes as Gilead is shifting focus to CAR-T—the Big Pharma is looking to make up for its flagging hepatitis C franchise, which is taking a hit from increased competition.
The next drug commodity play? China’s biopharmas crowding into a global PD-1/L1 free-for-all [EndPoints] PharmCube tells Endpoints News that Innovent Biologics, Shanghai Junshi, BeiGene (Celgene’s partner) and Jiangsu Hengrui are all being tipped for a market launch in the first half of 2019.
	5.12.6 Immunothérapies - AMM
Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma [BMS] Once approved, the Opdivo four-week dosing infused over 60 minutes would enable BMS to deliver on our promise to explore potentially more flexible and convenient dosing options for patients, caregivers and healthcare providers alike.
	5.2 Pharma
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer [Seattle Genetics] The Breakthrough Therapy Designation was granted based on interim results from the phase 1 study examining enfortumab vedotin as monotherapy treatment for patients with metastatic urothelial cancer who were previously treated with checkpoint inhibitors.
Bayer announces completion of rolling submission of New Drug Application in the U.S. for larotrectinib for the treatment of TRK fusion cancer [Bayer] Bayer and Loxo Oncology are jointly developing larotrectinib, an investigational compound being studied globally for the treatment of patients across a wide range of cancers that harbor an NTRK gene fusion.
AI. Telemedicine. Quantum. New Novartis Boss Says Tech Will Finally Change The Drug Biz [Forbes] The drug industry has generally been skeptical of tech's potential. But the new CEO insists that "going big on data and digital" will be one of the keys to Novartis' future.
FDA hands a ‘breakthrough’ designation to Seattle Genetics’ pivotal-stage cancer drug enfortumab [EndPoints] The drug is an antibody drug conjugate that targets nectin-4, which can be found on the surface of several solid tumors.
	5.4 Traitements - Economie
A billionaire couple is pumping money into the drug pricing debate. Can they loosen pharma’s grip? [STAT] Arnold, now a philanthropist with a technocratic bent, has been investing considerable money lately into projects aimed at lowering or rethinking drug prices — a populist cause more often associated with activists and patients than a rich guy who made his name in finance.
	6. Lutte contre les cancers
The people that make radiotherapy possible: Part 1 – therapy radiographers [Cancer Research UK] Kim Meeking has been treating people with cancer for 15 years. She’s a therapeutic radiographer, working at University Hospital Southampton, and here she shares what her job involves, and why she loves it.
The World Health Organization: Integrating quackery into the ICD-11 [Respectful Insolence] I doubt that even Mao could have imagined such a triumph of completely integrating International Classification of Traditional Medicine (ICTM) into the very codebook for modern medical diagnoses, the ICD-11, but that triumph will soon be upon us.
	6.1 Observation
Higher Risk of Heart Failure Seen in Some Cancers [NCI] Although the risk of developing heart failure was relatively low overall, people who had been treated for cancer had more than twice the risk of developing heart failure than those who had never had cancer, they found, and the risk was evident as early as one year after their cancer diagnosis. The increased risk persisted for at least 20 years.
	6.10.1 Politiques (USA)
A ‘right-to-try’ explainer [The Incidental Economist] If their outcomes are used by clinical drug trial sponsors in research, as allowed by the bill, the patients become (or are a lot like) research subjects. But, they are not protected by an IRB or U.S. federal research regulations.
	6.3 Associations/Fondations
She Was Given Three Years To Live. So She Transformed Cancer Research [Forbes] Giusti's survival has a lot to do with luck. Cancer is unpredictable. But it's also in part due to the philanthropic organization she founded in 1998, the Multiple Myeloma Research Foundation.
	6.7.1 Bioinformatique
Over 500 researchers granted access to the Genomics England Research Environment [Genomics England] Genomics England has also adopted the bioinformatics platform Galaxy, providing initial access to students on the MSc in Genomic Medicine course with thousands of genomic analysis tools.